Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Growth in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 14,600 shares, a growth of 124.6% from the October 31st total of 6,500 shares. Based on an average trading volume of 127,600 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are short sold.

Estrella Immunopharma Trading Up 3.0 %

ESLA stock traded up $0.03 during mid-day trading on Thursday, hitting $1.04. 19,166 shares of the company were exchanged, compared to its average volume of 75,850. The business has a 50 day simple moving average of $0.91 and a 200-day simple moving average of $1.09. The stock has a market capitalization of $37.63 million, a PE ratio of -4.00 and a beta of 0.24. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Friday, September 27th. The company reported ($0.13) earnings per share for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.